Uceris carries a retail price of roughly $1,760 for a single 30-day supply of 9 mg tablets, making it one of the pricier prescriptions in the ulcerative colitis space. Several factors drive that number: a specialized drug delivery system, the pricing strategy of its manufacturer, and limited competitive pressure even after generic versions became available.
What Makes Uceris Different From Other Budesonide
Budesonide itself is not an expensive molecule. It’s a well-established steroid used in inhalers, nasal sprays, and oral capsules for conditions like Crohn’s disease. What sets Uceris apart is its Multi-Matrix System (MMX) technology. Each tablet has an enteric coating that prevents the drug from breaking down in stomach acid, then a core of mixed polymers that controls how the budesonide releases further down the digestive tract. The goal is to deliver the steroid directly to the colon, where ulcerative colitis inflammation occurs, rather than letting it absorb higher up in the gut.
This targeted delivery is the clinical justification for the price premium. Entocort EC, another oral budesonide product, releases the drug in the small intestine for Crohn’s disease. Uceris is specifically designed, and FDA-approved, for active ulcerative colitis. The two products are not interchangeable, which means patients with UC can’t simply switch to a cheaper budesonide formulation meant for a different part of the GI tract.
Patent Protection and Delayed Competition
Uceris was approved by the FDA in 2013 under NDA 203634. Its last qualifying patent didn’t expire until June 2020, giving the manufacturer seven years of market exclusivity. During that window, no generic competitor could legally enter the market, allowing the brand to set prices without competitive pressure.
Even after 2020, generic entry has been slow to meaningfully drive down costs. A generic version of budesonide extended-release 9 mg tablets does exist, but generic pricing for specialty formulations with complex release mechanisms tends to stay higher than generics for simpler drugs. The MMX delivery system requires manufacturers to replicate a specific coating and polymer matrix to meet FDA bioequivalence standards, which narrows the field of companies willing and able to produce it.
Bausch Health’s Pricing Strategy
Uceris is marketed through Salix Pharmaceuticals, a subsidiary of Bausch Health (formerly Valeant Pharmaceuticals). Bausch Health has a well-documented history of acquiring specialty drugs and maintaining aggressive pricing. Their gastrointestinal portfolio, which includes other high-cost drugs, relies on what the company describes as “improved net pricing” as a core revenue strategy. In financial filings, Bausch Health explicitly ties segment performance to pricing decisions and changes in sales deductions, meaning the gap between gross price and what insurers actually pay is itself a strategic lever.
This approach is common among specialty pharma companies that hold products with limited therapeutic alternatives. Because Uceris occupies a narrow niche (oral steroid therapy specifically for ulcerative colitis flares), there’s less market pressure to lower the price compared to a drug with dozens of competitors.
What a Full Treatment Course Costs
Uceris is typically prescribed as an 8-week induction course at one 9 mg tablet per day. At the per-unit acquisition cost of about $58.41 per tablet, that works out to roughly $3,500 for a complete treatment course at retail price. For patients paying out of pocket or facing high-deductible insurance plans, this is a significant financial hit for what amounts to a short-term therapy.
On major insurance formularies, Uceris tends to land on Tier 3, the preferred brand tier. UnitedHealthcare’s 2025 prescription drug list, for example, places Uceris Oral on Tier 3 without noted prior authorization requirements. Tier 3 typically means higher copays than generics but lower than specialty tier drugs, so insured patients generally won’t pay the full retail price. Still, copays for Tier 3 brand drugs often run $50 to $100 or more per fill depending on the plan.
Generic and Savings Options
If your pharmacy is dispensing brand-name Uceris when a generic is available, ask about substitution. Generic budesonide extended-release tablets should cost meaningfully less, though “less” in this category may still mean hundreds of dollars without insurance.
For patients who are uninsured or on government insurance programs like Medicare or Medicaid, Pfizer’s RxPathways patient assistance program covers some Pfizer-affiliated medications for households earning at or below 300% of the federal poverty level. Eligibility requires that you’ve already applied to other available funding sources first. Commercially insured patients don’t qualify for this particular program. Medicare Part D patients may benefit from the Medicare Prescription Payment Plan, which caps annual out-of-pocket costs at $2,100 for most enrollees starting in recent plan years.
Why Switching Isn’t Always Simple
Patients sometimes wonder why they can’t just use a cheaper steroid or a different budesonide product. The short answer is that ulcerative colitis affects the colon, and most oral steroids either absorb systemically (causing more side effects) or release in the wrong part of the intestine. Systemic steroids like prednisone are far cheaper but come with a heavier side-effect burden: weight gain, bone loss, blood sugar spikes, mood changes. Uceris was designed to minimize those systemic effects by keeping the drug localized.
For mild to moderate UC flares, Uceris fills a specific role as a short-term induction therapy. It’s not a maintenance drug, so the cost is time-limited. But for patients who flare repeatedly and need multiple courses, those costs add up fast. Discussing both the generic option and therapeutic alternatives with your gastroenterologist is the most direct path to managing the expense.